SUBSCRIBE
SUBSCRIBE

IgA nephropathy

Entrance to Vertex's office in Boston, Massachusetts
Deals
Vertex Buys Alpine for $4.9B to Bolster Autoimmune and Inflammatory Disease Pipeline
Vertex Pharmaceuticals on Wednesday announced it is acquiring clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash, the largest acquisition so far this year.
April 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
April 29, 2025
 · 
6 min read
Press Releases
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
April 29, 2025
 · 
7 min read
Press Releases
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
April 28, 2025
 · 
4 min read
Press Releases
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
April 4, 2025
 · 
6 min read
Press Releases
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
April 3, 2025
 · 
21 min read
Press Releases
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
April 1, 2025
 · 
9 min read
Press Releases
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
March 26, 2025
 · 
12 min read
Press Releases
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
March 12, 2025
 · 
5 min read
Press Releases
BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
February 25, 2025
 · 
4 min read
Press Releases
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
January 10, 2025
 · 
6 min read
Press Releases
Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
November 20, 2024
 · 
6 min read
Press Releases
BioCity presents late-breaking clinical trial results with SC0062 for IgA Nephropathy at ASN Kidney Week 2024 as published in the Journal of the American Society of Nephrology
November 5, 2024
 · 
6 min read
Press Releases
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 28, 2024
 · 
16 min read
Press Releases
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
October 28, 2024
 · 
7 min read
Press Releases
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
October 23, 2024
 · 
5 min read
Press Releases
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
 · 
14 min read
Press Releases
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
October 17, 2024
 · 
4 min read
Press Releases
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 15, 2024
 · 
17 min read
Press Releases
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 10, 2024
 · 
6 min read
Press Releases
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
October 2, 2024
 · 
7 min read
Load More